Local tumour control and patient survival after ruthenium-106 brachytherapy for small choroidal melanoma

Ocular Oncology

Long-term visual outcomes and side effects of ruthenium plaque brachytherapy in 310 eyes with small choroidal melanoma

Br J Ophthalmol

Gallo B, Hussain R, Al-Jamal R, Khalid H, Stoker I, Hay G, Arora AK, Sagoo MS

doi: 10.1136/bjo-2023-324686

Ocular Oncology

Choroidal melanoma patient views on the importance of treatment characteristics and outcomes, and physicians' information provision in the Netherlands

Acta Ophthalmol

Shirzada A, Pieterse AH, Vlug L, Luyten GPM, Vu THK, Bleeker JC, Bakker PA, Marinkovic M, Rasch CRN, Horeweg N, van den Akker-Van Marle ME

doi: 10.1111/aos.17505

Ocular Oncology

Metastasis-free survival of uveal melanoma by tumour size category based on The Cancer Genome Atlas (TCGA) classification in 1001 cases

Clin Exp Ophthalmol

Bansal R, Sener H, Ganguly A, Shields JA, Shields CL

doi: 10.1111/ceo.14446

Blindness and Vision ImpairmentOcular OncologySurgery and InterventionCataracts

Association of female sex with cataract surgery in the general population but not in plaque brachytherapy-treated uveal melanoma patients

Sci Rep

Hagström A, Sabazade S, Gill V, Stålhammar G

doi: 10.1038/s41598-024-73346-3

Ocular OncologySurgery and Intervention

Inadvertent Scleral Perforation During Choroidal Melanoma Surgeries: Incidence, Risk Factors, Management, and Outcomes: Scleral Perforation in Melanoma Surgery

Am J Ophthalmol

Chou HD, Heimann H, Damato BE, Hussain RN

doi: 10.1016/j.ajo.2025.05.043

Ocular Oncology

Choroidal nevi and melanoma doubling times and implications for delays in treatment: A systematic review and meta-analysis

Surv Ophthalmol

Stålhammar G, Hagström A, Conradi ME, Williams PA

doi: 10.1016/j.survophthal.2024.09.004

Ocular Oncology

Performance of the MOLES and TFSOM-DIM scores in classifying choroidal nevi and melanoma

Sci Rep

Jahnke D, Grohmann C, Fuisting B, Skevas C, Spitzer MS, Birtel J

doi: 10.1038/s41598-024-78692-w

Ocular Oncology

Higher AJCC stage at primary tumor diagnosis may predict shorter survival in metastatic uveal melanoma

Sci Rep

Yavuzyigitoglu S, Sabazade S, Gill V, Brosens E, Kiliç E, Stålhammar G

doi: 10.1038/s41598-025-03961-1

Lenses

Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine

Br J Ophthalmol

Guemes-Villahoz N, Talavero González P, Porras-Ángel P, Bella-Gala R, Ruiz-Pomeda A, Martin-Garcia B, Hernandez-Garcia E, Gomez de Liaño N, Shah R, Garcia-Feijoo J, Gomez-de-Liaño R

doi: 10.1136/bjo-2024-326852

Related content

Long-term visual outcomes and side effects of ruthenium plaque brachytherapy in 310 eyes with small choroidal melanoma

Choroidal melanoma patient views on the importance of treatment characteristics and outcomes, and physicians' information provision in the Netherlands

Metastasis-free survival of uveal melanoma by tumour size category based on The Cancer Genome Atlas (TCGA) classification in 1001 cases

Association of female sex with cataract surgery in the general population but not in plaque brachytherapy-treated uveal melanoma patients

Inadvertent Scleral Perforation During Choroidal Melanoma Surgeries: Incidence, Risk Factors, Management, and Outcomes: Scleral Perforation in Melanoma Surgery

Choroidal nevi and melanoma doubling times and implications for delays in treatment: A systematic review and meta-analysis

Performance of the MOLES and TFSOM-DIM scores in classifying choroidal nevi and melanoma

Higher AJCC stage at primary tumor diagnosis may predict shorter survival in metastatic uveal melanoma

Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine